Arbaclofen placarbil

Arbaclofen placarbil ( , also known as XP19986) is a prodrug of "R"-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.
It is being developed as an addiction medicine to treat alcoholism. 